+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
288 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.

Age: 18Years +All GendersPhase 3
145 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
241 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of CCM therapy in treating heart failure in a real-world setting. This global, observational study includes both prospective and retrospective patients who have received or will receive CCM therapy using Impulse Dynamics systems, including future technologies such as CCM-D. Participants will be followed for at least 5 years to gather comprehensive data. Participants receive CCM therapy through an Impulse Dynamics device as part of their regular care. The study does not assign treatments but observes patients who have been implanted or will be implanted with these devices. The registry collects data from multiple centers worldwide, tracking outcomes over time without altering the standard treatment process. During the study, participants will be monitored regularly to assess hospitalizations related to heart failure, device- or procedure-related complications, mortality, functional capacity, and quality of life among other measures. Assessments include questionnaires like the Kansas City Cardiomyopathy Questionnaire and evaluations of clinical outcomes, device compliance, and cardiovascular changes. Follow-up will last for at least five years, ensuring long-term safety and effectiveness data collection.

Age: 18Years +All Genders
30 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
E

Actively Recruiting

Researchers are evaluating treatment options for younger patients with intermediate risk acute myeloid leukemia AML in this phase II trial. The study compares three different drug combinations cytarabine with daunorubicin cytarabine with daunorubicin plus venetoclax and venetoclax with azacitidine. The goal is to see if adding venetoclax improves the elimination of leukemia cells compared to the usual treatment, by measuring undetectable residual disease after therapy. Participants are randomly assigned to one of three treatment groups. One group receives daunorubicin and cytarabine with venetoclax over 28-day cycles, possibly followed by reinduction therapy based on bone marrow assessments. The second group receives azacitidine combined with venetoclax for two 28-day cycles. The third group receives daunorubicin and cytarabine alone, with potential reinduction treatment. Patients undergo bone marrow aspiration, blood sample collection, and heart function tests before and during the study. During the trial, participants will have regular evaluations including bone marrow tests and blood draws to monitor treatment effects and disease status. Heart function is assessed at screening with echocardiography or a MUGA scan. After completing treatment, patients are followed with visits at 4 weeks, every 3 months for the first year, every 6 months in the second year, and yearly thereafter. Researchers track remission rates, toxicities, survival outcomes, and responses based on genetic features for up to 10 years.

Age: 18Years - 59YearsAll GendersPhase 2
187 locations

1-10 of 40

1